Skip to main content
Figure 2 | BMC Nephrology

Figure 2

From: Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients

Figure 2

Serum phosphate levels. (A) during the open-label, lanthanum carbonate dose-titration phase (safety set); (B) during the randomized, placebo-controlled, parallel-group phase (per protocol set). *p < 0.01 vs placebo. Data are presented as mean ± 95% confidence interval.

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us